10x Genomics (TXG) Change in Receivables (2018 - 2026)

10x Genomics' Change in Receivables history runs 9 years deep, the most recent figure standing at -$18.1 million for Q1 2026.

• In Q1 2026, Change in Receivables changed N/A year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at $16.7 million (up 587.48% YoY), while the FY2025 annual figure was $34.9 million, up 229.4% from the prior year.
• Change in Receivables came in at -$18.1 million for Q1 2026 at 10x Genomics, down from -$17.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $90.1 million in Q3 2025 to a low of -$37.9 million in Q2 2025.
• A 5-year average of $1.2 million and a median of -$209500.0 in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables surged 3383.84% in 2023 and slumped 30979.51% in 2025, its largest moves.
• 10x Genomics' Change in Receivables stood at $20.6 million in 2022, then plunged by 46.78% to $11.0 million in 2023, then tumbled by 60.18% to $4.4 million in 2024, then slumped by 496.66% to -$17.3 million in 2025, then decreased by 4.59% to -$18.1 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$18.1 million, -$17.3 million, and $90.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison